A study published in Nature Medicine in early 2019 describes a novel cancer vaccine that positively affected three out of eleven Lymphoma patients. The researchers describe the treatment as a vaccine because it causes the patient’s immune system to fight the cancer, even though it is not preventative. In these three patients, the vaccine was not only able to shrink the tumor being treated directly, but also other tumors present throughout the body. This clinical trial, although promising, is not large enough for the vaccine to be reviewed for approval by the FDA. As such, researchers must conduct further tests before this treatment becomes commercially available.